EU/3/19/2182

About

On 25 July 2019, orphan designation EU/3/19/2182 was granted by the European Commission to Genfit, France, for elafibranor for the treatment of primary biliary cholangitis.

Key facts

Active substance
Elafibranor
Disease / condition
Treatment of primary biliary cholangitis
Date of first decision
25/07/2019
Outcome
Positive
EU designation number
EU/3/19/2182

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Genfit
Parc Eurasante Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel: +33(0) 3 20 16 40 50
E-mail: emmanuel.lechat@genfit.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating